A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer

Chi, KN; Rathkopf, D; Smith, MR; Efstathiou, E; Attard, G; Olmos, D; Lee, JY; Small, EJ; Pereira de Santana Gomes, AJ; Roubaud, G; Saad, M; Zurawski, B; Sakalo, V; Mason, GE; Francis, P; Wang, G; Wu, D; Diorio, B; Lopez-Gitlitz, A; Sandhu, S

Author(s): Chi, KN; Rathkopf, D; Smith, MR; Efstathiou, E; Attard, G; Olmos, D; Lee, JY; Small, EJ; Pereira de Santana Gomes, AJ; Roubaud, G; Saad, M; Zurawski, B; Sakalo, V; Mason, GE; Francis, P; Wang, G; Wu, D; Diorio, B; Lopez-Gitlitz, A; Sandhu, S;
Details: Publication Year 2025-04,Volume 21,Issue #9,Page 1013-1031
Journal Title: Future Oncology
Publication Type: Commentary
Abstract: What is this summary about?; This is a summary of the MAGNITUDE clinical study that was published in the Journal of Clinical Oncology (March 2023) and in Annals of Oncology (September 2023).; Researchers looked at the combination of niraparib and abiraterone acetate with prednisone as a first treatment for adult patients with metastatic castration-resistant prostate cancer.; Researchers wanted to know how effective and safe niraparib + abiraterone acetate with prednisone is in patients whose cancers had certain gene changes.; Researchers focused on genes related to homologous recombination repair (HRR), a normal process that repairs damaged DNA.; The best understood HRR genes are BRCA1 and BRCA2 (which code for BReast CAncer susceptibility 1 and 2 proteins) that are changed in 3–13% of patients with metastatic castration-resistant prostate cancer. We refer to these genes as BRCA1/2.; Compared with cancers that lack these changes, cancers with changes in HRR genes (HRR+) may not respond as well to treatments that are normally used for metastatic castration-resistant prostate cancer, such as abiraterone acetate with prednisone.; What were the main conclusions reported by the researchers?; Patients who had BRCA1/2 changes had a longer time (16.6 months) before their cancer worsened compared with those who did not (10.9 months).; Patients with HRR+ metastatic castration-resistant prostate cancer taking niraparib + abiraterone acetate with prednisone had a longer time (16.5 months) before their cancer worsened (tumor increased in size, cancer spread, or death) compared with those taking placebo + abiraterone acetate with prednisone (13.7 months).; Patients taking niraparib + abiraterone acetate with prednisone had more side effects (99.1%) than those taking placebo + abiraterone acetate with prednisone (94.3%).; These were well-known side effects of these medicines and generally managed by pausing treatment or lowering the dose.; What are the key takeaways?; Patients with HRR+ metastatic castration-resistant prostate cancer, especially those with BRCA1/2 changes, have better outcomes with niraparib + abiraterone acetate with prednisone compared with placebo + abiraterone acetate with prednisone.; These results show the importance of testing for HRR gene changes to select treatments that are most likely to lead to improved outcomes for these patients.
Publisher: Taylor & Francis
Department(s): Medical Oncology
Publisher's Version: https://doi.org/10.1080/14796694.2025.2470106
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2026-01-09 05:37:24

Last Modified: 2026-01-09 05:38:15